Drugs / DENVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01224639 | Oct 2010 → Jun 2011 | dengue disease | Inviragen Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DENVax | “The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults” NCT01224639 ↗ |
| Known as | TDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01224639 ↗ |
| Route | Other | “administered subcutaneously” NCT01224639 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT01224639 ↗ |